The procedure for psychedelic therapy differs from that of therapies using conventional psychiatric medications. While conventional medications are usually taken without supervision at least once daily, in contemporary psychedelic therapy the drug is administered in a single session (or sometimes up to three sessions) in a therapeutic context.[8] The therapeutic team prepares the patient for the experience beforehand and helps them integrate insights from the drug experience afterwards.[9][10] After ingesting the drug, the patient normally wears eyeshades and listens to music to facilitate focus on the psychedelic experience, with the therapeutic team interrupting only to provide reassurance if adverse effects such as anxiety or disorientation arise.[9][10]
As of 2022, the body of high-quality evidence on psychedelic therapy remains relatively small and more, larger studies are needed to reliably show the effectiveness and safety of psychedelic therapy's various forms and applications.[11][12][5] On the basis of favorable early results, ongoing research is examining proposed psychedelic therapies for conditions including major depressive disorder,[11][13]anxiety and depression linked to terminal illness,[11][14] and post-traumatic stress disorder.[12][15] The United States Food and Drug Administration has granted "breakthrough therapy" status, which expedites the potential approval of promising drug therapies,[note 2] to psychedelic therapies using psilocybin (for treatment-resistant depression and major depressive disorder)[6] and MDMA (for post-traumatic stress disorder).[17]
^ abGarcia-Romeu A, Richards WA (August 2018). "Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions". International Review of Psychiatry. 30 (4): 291–316. doi:10.1080/09540261.2018.1486289. PMID30422079. S2CID53291327.
^ abcBender D, Hellerstein DJ (January 2022). "Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research". Psychopharmacology. 239 (6): 1907–1932. doi:10.1007/s00213-021-06049-6. PMID35022823. S2CID245906937.
^ abSmith KW, Sicignano DJ, Hernandez AV, White CM (April 2022). "MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis". Journal of Clinical Pharmacology. 62 (4): 463–471. doi:10.1002/jcph.1995. PMID34708874. S2CID240072663.
^Romeo B, Karila L, Martelli C, Benyamina A (October 2020). "Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis". Journal of Psychopharmacology. 34 (10): 1079–1085. doi:10.1177/0269881120919957. PMID32448048. S2CID218873949.
^"Breakthrough Therapy". United States Food and Drug Administration. 1 April 2018. Archived from the original on 1 March 2022. Retrieved 27 March 2022.
Cite error: There are <ref group=note> tags on this page, but the references will not show without a {{reflist|group=note}} template (see the help page).